Mr Whispers

Here is a piece that pretty much narrows down the day.

https://mrwhispers.abacusai.app/insights/direct-challenge-to-the-balanyce-of-powers-data-defiance-and-the-10-snap-back-mlvnxn8t

Stock Whispers - #1 OTC & Penny Stock Alerts | Join 80K+ Traders Get exclusive stock alerts, breakout picks, and market intelligence delivered daily. Join 80,000+ active traders. Free to join.

The Whispers from the Frontline: Why $DFNS is the Sleeper to Watch
The drums of war are beating louder, and in the world of Mr. Whispers, silence is usually the loudest warning.

https://mrwhispers.abacusai.app/insights/the-whispers-from-the-frontline-why-dfns-is-the-sleeper-to-watch-mltxnrov

The Whispers from the Frontline: Why $DFNS is the Sleeper to Watch The drums of war are beating louder, and in the world of Mr. Whispers, silence is usually the loudest warning.

Date: February 17, 2026 If you got whiplash today, you aren’t alone.
The market didn’t know if it wanted to sprint or faint, But let’s be honest about that close: we clawed back to "nominal gains," but it felt like running through mud.

You want to know why

Date: February 17, 2026 If you got whiplash today, you aren’t alone. The market didn’t know if it wanted to sprint or faint, But let’s be honest about that close: we clawed back to "nominal gains," but it felt like running through mud.

Iran-US Tensions: Keep Your Finger Off the Panic Button

https://mrwhispers.abacusai.app/insights/iran-us-tensions-keep-your-finger-off-the-panic-button-mlquolif

Iran-US Tensions: Keep Your Finger Off the Panic Button Deep breaths, folks. Yes, the Strait of Hormuz is getting spicy. Yes, there's a second carrier group steaming toward the Middle East. But here's what the headlines won't tell you: talks are happening right now in Geneva.

Don't fight the flow. The whale has surfaced. 🐋📈

Mr. Whispers Alert: The $BRTX "Bear Trap" & The Whale in the Water 🐋 Date: February 13, 2026 The Setup: From "Falling Knife" to "Banker Reclaim"

$STFS is showing all the signs of a "sympathy runner." It’s cheap, it’s bottomed, and it’s in the right sector. Watch for volume to spike early in the session—that’s your signal.
https://mrwhispers.abacusai.app/insights/runners-are-back-mlki9n3w

Ehave, Inc.: A New Direction in 2025 Ehave Inc. Now complaint with it's SEC requirements and hinting at a new direction. Listen to the excitement!

https://finance.yahoo.com/news/consumer-expectations-for-stocks-hit-three-year-high-in-may-174031824.html

Consumer expectations for stocks hit three-year high in May Consumer expectations for stocks hit a three-year high amid a roaring rally on Wall Street to start 2024.

Mira Pharma is at the forefront of mental health therapeutics. Mira Pharmaceuticals' commitment to addressing the unmet needs in neurologic and neuropsychiatric disorders, coupled with promising preclinical results for Ketamir-2, suggests potential for significant market impact and growth. The appointment of Dr. Itzchak Angel, a distinguished pharmaceutical executive, as Chief Scientific Advisor further enhances the company's scientific capabilities and credibility. Dr. Angel's extensive experience and track record of advancing groundbreaking medications are expected to accelerate Mira Pharmaceuticals' research and development pipeline, potentially leading to the introduction of innovative therapies that could reshape the treatment landscape for mental health disorders.

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog Investigative studies are underway testing Ketamir-2 as the potential first at home ketamine analog treatment for PTSD, depression, and…...

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, tow...